PuSH - Publikationsserver des Helmholtz Zentrums München

Tinhofer, I.* ; Budach, V.* ; Saki, M.* ; Konschak, R.* ; Niehr, F.* ; Jöhrens, K.* ; Weichert, W.* ; Linge, A.* ; Lohaus, F.* ; Krause, M.* ; Neumann, K.* ; Endris, V.* ; Sak, A.* ; Stuschke, M.* ; Balermpas, P.* ; Rödel, C.* ; Avlar, M.* ; Grosu, A.-L.* ; Abdollahi, A.* ; Debus, J.* ; Belka, C.* ; Pigorsch, S.* ; Combs, S.E. ; Mönnich, D.* ; Zips, D.* ; Baumann, M.*

Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation.

Eur. J. Cancer 57, 78-86 (2016)
Postprint Anhang DOI PMC
Open Access Green
BACKGROUND: Despite clear differences in clinical presentation and outcome, squamous cell carcinomas of the head and neck (SCCHN) arising from human papilloma virus (HPV) infection or heavy tobacco/alcohol consumption are treated equally. Next-generation sequencing is expected to reveal novel targets for more individualised treatment. PATIENTS AND METHODS: Tumour specimens from 208 patients with locally advanced squamous cell carcinoma of the hypopharynx, oropharynx or oral cavity, all uniformly treated with adjuvant cisplatin-based chemoradiation, were included. A customised panel covering 211 exons from 45 genes frequently altered in SCCHN was used for detection of non-synonymous point and frameshift mutations. Mutations were correlated with HPV status and treatment outcome. RESULTS: Mutational profiles and HPV status were successfully established for 179 cases. HPV- tumours showed an increased frequency of alterations in tumour suppressor genes compared to HPV+ cases (TP53 67% versus 4%, CDKN2A 18% versus 0%). Conversely, HPV+ carcinomas were enriched for activating mutations in driver genes compared to HPV- cases (PIK3CA 30% versus 12%, KRAS 6% versus 1%, and NRAS 4% versus 0%). Hotspot TP53 missense mutations in HPV- carcinomas correlated with an increased risk of locoregional recurrence (hazard ratio [HR] 4.3, 95% confidence interval [CI] 1.5-12.1, P=0.006) and death (HR 2.2, 95% CI 1.1-4.4, P=0.021). In HPV+ SCCHN, driver gene mutations were associated per trend with a higher risk of death (HR 3.9, 95% CI 0.7-21.1, P=0.11). CONCLUSIONS: Distinct mutation profiles in HPV- and HPV+ SCCHN identify subgroups with poor outcome after adjuvant chemoradiation. Mutant p53 and the phosphoinositide 3-kinase pathway were identified as potential druggable targets for subgroup-specific treatment optimisation.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Adjuvant Chemoradiation ; Cisplatin ; Head And Neck Cancer ; Human Papilloma Virus ; Mutation Profiles; Hpv-negative Head; Mutant P53; Tumor-suppressor; Genomic Analysis; Cancer-patients; Tp53 Mutations; Rectal-cancer; Lung-cancer; Survival; Pathway
ISSN (print) / ISBN 0959-8049
e-ISSN 1879-0852
Zeitschrift European Journal of Cancer
Quellenangaben Band: 57, Heft: , Seiten: 78-86 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort Oxford
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Radiation Medicine (IRM)